CRP and neoplasm: The 1-, 3-, and 5-year DFS rate of the high ACR group were significantly higher than those of the low ACR group in tumor size < 5 cm subgroup (96.9, 81.6, 78.3% vs. 78.9, 47.8, 47.8%, respectively; p = 0.0003) (Fig. 4b), in early stage (stage Iand II) subgroup (93.3, 81.4, 79.1% vs. 71.8, 51.2, 51.2%, respectively, p <  0.0001) (Fig. 4d), in serum AFP level <  400 ng / mL subgroup (94.7, 77.5, 74.7% vs. 60.2, 40.0, 38.6%, respectively, p <  0.0001) (Fig. 4f), and in platelet / CRP <  47.8 subgroup (78.9, 58.2, 55.9% vs. 51.9, 33.8, 32.1%, respectively, p = 0.0009) (Fig. 4h).